Product Description
Mechanisms of Action: ELA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | Korea
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn
Phase 3: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Sepsis
Phase 2: Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2400086632 | N/A |
Not yet recruiting |
Unknown |
2027-04-24 |
|
ChiCTR2200059102 | N/A |
Not yet recruiting |
Acute Lung Injury |
2027-03-01 |
|
ChiCTR2400086486 | N/A |
Not yet recruiting |
Acute Respiratory Distress Syndrome |
2026-12-31 |
|
2023-LCYJ-MS-26 | P3 |
Not yet recruiting |
Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Acute Respiratory Distress Syndrome |
2026-06-30 |